Treatment for knee osteoarthritis in patients with oxalate nephropathy


Cite item

Full Text

Abstract

Aim. To elucidate the safety profile and symptom-modifying effect of Аlflutop and diacerein in the treatment of Kellgren—Lawrence Stages II—III knee osteoarthrosis (OA) in patients with oxalate nephropathy and Stages I—II chronic kidney disease (CKD) and to refine the effect of these drugs on urinary syndrome and renal function as compared to a response to nonsteroidal anti-inflammatory drugs — cyclooxygenase inhibitors (diclofenac). Subjects and methods. This open-label comparative randomized trial enrolled 86 female patients with Kellgren—Lawrence Stages II—III primary gonarthritis concurrent with oxalate nephropathy and Stages I—II CKD. The patients were randomized into 3 groups: 1) 20 patients took diclofenac sodium 100 mg/day; 2) 30 received a complex pharmaceutical on the basis of glycozaminoglycans Аlflutop injection 1 ml per day for 20 days, then 2 ml intraartricular twice weekly in the following month; 3) 36 had diacerein (diaflex, «Rompharm Company») in a dose of 50 mg twice daily for 3 months. On day 30 and day 90 of treatment, the symptom-modifying effect was evaluated from changes in the joint pain and morning stiffness domains of the WOMAC index. Renal function was measured using the estimated glomerular filtration rate (GFR), uric acid clearance (Cua), and urinary sediment. Results. On day 30 of treatment, the patients taking diclofenac were found to have nephrotoxic effects (lower GFR, Cua, evolving secondary hyperuricemia, progressive proteinuria, emerging microhematuria, elevated urinary levels of total lipid hydroperoxides, and enhanced calcium oxalate crystalluria). Alflutop and diacerein exerted no negative effects on renal function. On day 30 day of treatment, all the patient groups showed a reduction in the WOMAC pain score. The diclofenac group displayed a more marked decrease in the pain score than did the two other groups by day 30. Otherwise by day 90 of therapy with Аlflutop and diacerein, the pain scores were reduced by 60 and 67%, respectively, which was similar to those in the diclofenac group by day 30 of a follow-up. By day 30 day of treatment, the stiffness score was also observed to fall in all the groups and achieved even lower values in the Аlflutop and diacerein groups compared with diclofenac group.. Conclusion. Alflutop and diacerein used by patients with knee OA do not produce nephrotoxic effects and by day 90 demonstrated similar to diclofenac symptom-modifying effect by reducing pain and stiffness scores. Diclofenac administration contributed to oxalate nephropathy progress.

References

  1. Алексеева Л.И., Шарапова Е.П. Комбинированные препараты замедленного действия в терапии остеоартроза. Рус мед журн 2009; 3: 160—164.
  2. Matel-Pelletier J., Pelletier J.P. Effects of Diacerein at the molecular level in the Osteoarthritis Disease Process. Ther Adv Musculoskelet Dis 2010; 2 (2): 95—104.
  3. Чичасова Н.В. Лечение остеоартроза: влияние на хрящевую ткань различных противовоспалительных препаратов. Рус мед журн 2013; 3: 3—6.
  4. Алексеева Л.И., Шарапова Е.П., Таскина Е.А., Чичасова Н.В., Имаметдинова Г.Р., Шостак Н.А., Правдюк Н.Г., Денисов Л.Н. Многоцентровое слепое рандомизированное плацебо контролируемое исследование симптом- и структурно-модифицирующего действия препарата Алфлутоп у больных остеоартрозом коленных суставов. Сообщение 1. Научно-практич ревматология 2013; 5: 1—8.
  5. Martel-Pelletier J., Mineau F., Jolicoeur F.C., Cloutier J.M., Pelletier J.P. In vitro effects of Diacerhein and Rhein on IL-1 and TNF-a systems in human osteoarthritis synovium and chondrocytes. J Rheumatol 1998; 25: 753—762.
  6. Yaron М., Shirazi I., Yaron I. Anti-interleukin-1 effects of Diacerhein and Rhein in human osteoarthritis synovial tissue and cartilage cultures. Osteoarthritis Cartilage 1999; 7 (3): 272—280.
  7. Mendes A.F., Caramona M.M., de Carvalho A.P., Lopes MC. Diacerhein and Rhein prevent interleukin-1 b- induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alfa. Pharmacol Toxicol 2002; 91: 22—28.
  8. Martin G., Bogdanowicz P., Domagala F., Ficheux H., Pujol J.P. Rhein inhibits interleukin-1b-induced activation of MEK/ERK pathway and DNA binding of NF-kappa В and AP-1in chondrocytes cultured in hypoxia: potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation 2003; 27 (4): 233—246.
  9. Pavelka K., Olejarova M., Rovensky J. Randomized, placebo-controlled Study of Diacerhein in painful osteoarthritis of the knee-assessment of carry-over effect. Ann Rheum Dis 2005; 64 (3): 483—486.
  10. Martin G., Bogdanowicz P., Domagala F., Ficheux H., Pujol J.P. Rhein inhibits interleukin-1b-induced activation of MEK/ERK pathway and DNA binding of NF-kappa В and AP-1in chondrocytes cultured in hypoxia: potential mechanism for its disease-modifying effect in osteoarthritis. Biorheology 2006; 43 (3—4): 577—587.
  11. Leeb B.F, Rintelen B. A Systematic meta-analysis trials with Diacerhein in osteoarthritis. Osteoarthritis cartilage 2005; 3 (Suppl A): 68.
  12. Curhan G.C., Knight E.L., Rosner B., Hankinson S.E., Stampfer M.J. Lifetime Nonnarcotic Analgesic Use and Decline in Renal Function in Women. Arch Intern Med 2004; 164: 1519—1524.
  13. Tall M.W., Brenner B.M. Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney Int 2006; 70: 1694—1705.
  14. Шулутко Б.И., Макаренко С.В. Тубулоинтерстициальные воспалительные заболевания почек. Нефрология 2004; 1: 89—97.
  15. Батюшин М.М., Терентьев В.П., Дмитриева О.В., Повилайте П.Е. Хроническая болезнь почек: место нестероидных противовоспалительных препаратов. Элиста: Джангар 2009: 128.
  16. Андросова С.О., Фомин В.В., Шилов Е.М. Тубулоинтерстициальный нефрит. В кн.: Нефрология. Национальное руководство. М.: ГЭОТАР-Медиа 2009; 403—411.
  17. Воронина Н.В. Оксалатная нефропатия. В кн.: Нефрология. Национальное руководство. М.: ГЭОТАР-Медиа 2009; 412—421.
  18. Игнатова М.С. Диагностика и лечение нефропатий с оксалатно-кальциевой кристаллурией. В кн.: Нефрология. Руководство для врачей. М.: Медицина 2000; 354—356.
  19. Юрьева Э.А., Коровина Н.А., Казанская и др. Клинико-биохимические аспекты интерстициального нефрита при гипероксалурии. Вопр охраны материнства и детства 1983; 8: 13—18.
  20. Воронина Н.В., Грибовская Н.В., Евсеев А.Н. Оксалатная нефропатия: клинико-морфологические исследования. Хабаровск: изд-ние ДВГМУ 2014; 136.
  21. Ibanez L., Morlans M., Vidal X., Martinez M.J., Laporte J.-R. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end- stage renal disease. Kidney Int 2005; 67: 2393—2398.
  22. Harris R.C. Cyclooxygenase-2 in the Kidney. J Am Soc Nephrol 2000; 11: 2387—2394.
  23. Тареева И.Е., Мухин Н.А., Потапова А.В. Тубулоинтерстициальные поражения почек в нефрологической клинике. Клин мед 1994; 1: 64—67.
  24. Шилов Е., Андросова С.О. Лекарственные поражения почек. Врач 2002; 6: 47—49.
  25. Шулутко Б.И. Нефрология-2002: современное состояние проблемы. СПб: Ренкор 2002; 780.
  26. Breyer M.D., Hao C., Qi Z. Cyclooxygenase-2 selective inhibitors and the kidney. Curr Opin Crit Care 2001; 7 (6): 393—400.
  27. Deray G. Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective, cox 2 inhibitors. Presse Med 2004; 7 (10): 483—489.
  28. Galesic K., Moivvic-Vergles J., Jelakovic B. Nonsteroidal antirheumatics and the kidney. Reumatizam 2005; 52 (2): 61—66.
  29. Atmansori М.,Kovithavongs Т., Oami M.U. Cyclooxygenase-2 inhibitor-associated minimal- change disease. Clin Nephrol 2005; 63 (5): 381—384.
  30. Мухин Н.А., Тареева И.Е., Шилов Е.М. Диагностика и лечение болезней почек. М.: ГЭОТАР-Мед 2002: 384.
  31. Балкаров И.М., Лебедева М.В., Щербак А.В., Мухин Н.А. Клиника, диагностика и лечение хронического тубулоинтерстициального нефрита. Клин фармакология и терапия 2000; 9 (5): 81—85.
  32. Perazella M.A. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325 (6): 349—362.
  33. McAlindon T.E. et al. OARSI guidelines for non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage 2014; 22 (3): 363—388.
  34. Dougados M., Nguyen M., Berdah L., Maziéres B., Vignon E., Lequesne M.; ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001; 44 (11): 2539—2547.
  35. А. В. Смирнов, Е. М. Шилов, В. А. Добронравов, И. Г. Каюков, И. Н. Бобкова, М. Ю. Швецов, А. Н. Цыгин, А. М. Шутов. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клиническая нефролгия 2012;4: 4-26.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies